Xueying Shen

1 Introduction The identification of neoantigens has transformed cancer vaccine development by enabling precise activation of tumor-specific T cells.[1-3] Among various platforms, peptide-based vaccines have attracted interest due to their favorable safety, stability, and manufacturing profiles.[4-8] However, their clinical efficacy remains limited by poor lymph node accumulation and rapid clearance following subcutaneous or intramuscular injection,[9] which restricts their ability to elicit...